BACKGROUND: Partial Rh antigens have been widely described in black individuals. Carriers are prone to immunization when exposed to the normal antigens. In sickle cell disease (SCD), patient alloimmunization is a major cause of transfusion failure. The potential of individuals with partial C antigen to make anti-C has not been investigated. We sought partial C status and anti-C production in a cohort of SCD patients with the C+ phenotype, to determine whether exposure to normal C antigen should be avoided. STUDY DESIGN AND METHODS: We constituted a cohort of 177 randomly selected SCD patients expressing C antigen. We screened for (C)ce(s) and R(N) haplotypes, presumably associated with partial C antigen in Afro-Caribbeans, and we recorded the number of transfused C+ red blood cell (RBC) units, immunization status, and extended phenotype. RESULTS: Forty-nine patients carried abnormal C antigen, deduced from the presence of (C)ce(s) and/or R(N), not compensated by a normal RHC allele in trans. Among patients with partial C phenotype exposed repeatedly to C+ RBCs, 30% produced anti-C. Two patients experienced hemolysis. In our hospital, with 22% of SCD patients expressing C, prevention of anti-C immunization for all individuals with partial C antigen would require a 7% increase in the use of C- RBC units. These RBCs are already in short supply for SCD patients who are C-. CONCLUSION: This study demonstrates the need to detect partial C within C+ SCD patients and to prevent immunization. A larger number of Afro-Caribbeans donors is needed to provide these patients with C- RBCs.
BACKGROUND: Partial Rh antigens have been widely described in black individuals. Carriers are prone to immunization when exposed to the normal antigens. In sickle cell disease (SCD), patient alloimmunization is a major cause of transfusion failure. The potential of individuals with partial C antigen to make anti-C has not been investigated. We sought partial C status and anti-C production in a cohort of SCDpatients with the C+ phenotype, to determine whether exposure to normal C antigen should be avoided. STUDY DESIGN AND METHODS: We constituted a cohort of 177 randomly selected SCDpatients expressing C antigen. We screened for (C)ce(s) and R(N) haplotypes, presumably associated with partial C antigen in Afro-Caribbeans, and we recorded the number of transfused C+ red blood cell (RBC) units, immunization status, and extended phenotype. RESULTS: Forty-nine patients carried abnormal C antigen, deduced from the presence of (C)ce(s) and/or R(N), not compensated by a normal RHC allele in trans. Among patients with partial C phenotype exposed repeatedly to C+ RBCs, 30% produced anti-C. Two patients experienced hemolysis. In our hospital, with 22% of SCDpatients expressing C, prevention of anti-C immunization for all individuals with partial C antigen would require a 7% increase in the use of C- RBC units. These RBCs are already in short supply for SCDpatients who are C-. CONCLUSION: This study demonstrates the need to detect partial C within C+ SCDpatients and to prevent immunization. A larger number of Afro-Caribbeans donors is needed to provide these patients with C- RBCs.
Authors: Ross M Fasano; Alessandro Monaco; Emily Riehm Meier; Philippe Pary; A Hallie Lee-Stroka; John Otridge; Harvey G Klein; Francesco M Marincola; Naynesh R Kamani; Naomi L C Luban; David Stroncek; Willy A Flegel Journal: Blood Date: 2010-07-19 Impact factor: 22.113
Authors: Carla L Dinardo; Shannon Kelly; Marcia R Dezan; Ingrid H Ribeiro; Shirley L Castilho; Luciana C Schimidt; Maria do C Valgueiro; Liliana R Preiss; Brian Custer; Ester C Sabino; Connie M Westhoff Journal: Transfusion Date: 2019-08-13 Impact factor: 3.157
Authors: Ti-Cheng Chang; Kelly M Haupfear; Jing Yu; Evadnie Rampersaud; Vivien A Sheehan; Jonathan M Flanagan; Jane S Hankins; Mitchell J Weiss; Gang Wu; Sunitha Vege; Connie M Westhoff; Stella T Chou; Yan Zheng Journal: Blood Adv Date: 2020-09-22
Authors: Stella T Chou; Jonathan M Flanagan; Sunitha Vege; Naomi L C Luban; R Clark Brown; Russell E Ware; Connie M Westhoff Journal: Blood Adv Date: 2017-08-03